ATC Group: R01AX06 Mupirocin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R01AX06 in the ATC hierarchy

Level Code Title
1 R Respiratory system
2 R01 Nasal preparations
3 R01A Decongestants and other nasal preparations for topical use
4 R01AX Other nasal preparations
5 R01AX06 Mupirocin

Active ingredients in R01AX06

Active Ingredient

Mupirocin is a novel antibiotic produced through fermentation by Pseudomonas fluorescens. Mupirocin inhibits isoleucyl transfer-RNA synthetase, thereby arresting bacterial protein synthesis. Mupirocin has bacteriostatic properties at minimum inhibitory concentrations and bactericidal properties at the higher concentrations reached when applied locally.

Related product monographs

Document Type Information Source  
 BACTROBAN 2% Cream MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 BACTROBAN Nasal ointment MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)

Medicines in this ATC group

Australia (AU)

Austria (AT)

Brazil (BR)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Malta (MT)

Mexico (MX)

New Zealand (NZ)

Poland (PL)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.